123I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: Results and perspectives of a multicenter phase III clinical trial

38Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

Abstract

Our group has developed a new radiopharmaceutical, 123I-N-(2- diethylaminoethyl)-2-iodobenzamide (123I-BZA2), a benzamide derivative able to bind to melanin pigment in melanoma cells. In a prospective and multicentric phase III clinical study, the value of 18F-FDG PET/CT and 123I-BZA2 scintigraphy was compared for melanoma staging. Methods: Patients with a past history of cutaneous or ocular melanoma were included from 8 hospitals. 18F-FDG imaging was performed according to a standard PET protocol. Whole-body, static planar, and SPECT/CT (if available) images were acquired 4 h after injection of a - MBq/kg dose of 123I-BZA2. 18F-FDG and 123I-BZA2 sensitivity and specificity for the diagnosis of melanoma metastasis were calculated and compared on both a lesion basis and a patient basis. True-positive and true-negative lesion status was determined after ± mo of clinical follow-up or according to lesion biopsies (if available). Melanin content in biopsies was evaluated with the standard Fontana-Masson silver method and was correlated with 123IBZA2 uptake. Based on statistical analysis, the number of inclusions was estimated at 186. Results: In all, 87 patients were enrolled from 2008 to 2010. Of these, 45 (52%) had metastases. A total of 338 imaging abnormalities were analyzed; 86 lesions were considered metastases, and 20 of 25 lesion biopsies found melanoma metastases. In a patient-based analysis, the sensitivity of 18F-FDG for diagnosis of melanoma metastases was higher than that of 123I-BZA2, at 87% and 39%, respectively (P < 0.05). For specificity, 18F-FDG and 123I-BZA2 were not statistically different, at 78% and 94%, respectively. In a lesion-based analysis, the sensitivity of 18F-FDG was statistically higher than that of 123I-BZA2 (80% vs. 23%, P < 0.05). The specificity of 18F-FDG was lower than that of 123I-BZA2 (54% vs. 86%, P < 0.05). According to biopsy analysis, only 9 of 20 metastatic lesions (45%) were pigmented with high melanin content. 123I-BZA2 imaging was positive for ± of 8 melanin-positive lesions, fairly positive for 3 of 10 melanin-negative lesions, and negative for 7 of 10 melaninnegative lesions. The sensitivity and specificity of 123I-BZA2 for the diagnosis of melanin-positive lesions were 75% and 70%, respectively. Because of a low 123I-BZA2 sensitivity, this clinical trial was prematurely closed after 87 patients had been included. Conclusion: This study confirms the value of 18F-FDG PET/CT for melanoma staging and strengthens the high accuracy of 123I-BZA2 for diagnosis of melanin-positive metastatic melanoma. Moreover, benzamide derivatives radiolabeled with therapeutic radionuclide may offer a new strategy for the treatment of metastatic melanoma patients harboring melanin-positive metastases. Copyright © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author supplied keywords

Cite

CITATION STYLE

APA

Cachin, F., Miot-Noirault, E., Gillet, B., Isnardi, V., Labeille, B., Payoux, P., … D’incan, M. (2014). 123I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: Results and perspectives of a multicenter phase III clinical trial. Journal of Nuclear Medicine, 55(1), 15–22. https://doi.org/10.2967/jnumed.113.123554

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free